Occidental and Enterprise Products Partners have both seen a lot of insider stock trading activity. Read more about these ...

Blackstone's shares have fallen 19.7%, but fee-related earnings grew 21%. See why BX stock is now a "Buy" after our downgrade ...

Investing.com-- Asian currencies were a mixed bag on Wednesday amid persistent concerns over a brewing trade war between the U.S. and China, although hawkish wage data sparked a rally in the ...

One of the most notable additions is Gemini's ability to generate graphs based on spreadsheet data. Users can instruct the AI to create visual representations, such as a chart of segments by ...

RUNNER-UP: Fool Me Once, Netflix, 10.89 billion minutes ARTEY WINNER: Nobody Wants This, Netflix, 4.90 billion minutes Netflix rom-com Nobody Wants This enjoyed three weeks atop Nielsen’s streaming ...

Musk’s comments about the Holocaust to a far-right German party probably aren’t helping. [email protected] Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ...

The measurement giant last week won accreditation from the Media Rating Council, an industry monitor, for a new “Panel + Big Data” offering that will incorporate audience interactions with ...

Nielsen wants customers to begin fulfilling those needs using a newer ratings product called Big Data + Panel, which combines the panel-based consumer data with numbers drawn from third-party ...

We define a Data Lakehouse architecture with the following layers: Raw: Contains raw data files directly ingested from an event stream, e.g. Kafka. This data should generally not be accessible (can ...

This marks the first accredited hybrid panel/big-data product and is widely adopted for planning and cross-platform audience analysis, essential for the evolving media marketplace. The Media Rating ...

Yet, the long-term impact remains uncertain with the investment bank flagging the risk of shifting away from outsourced data centers. If OpenAI, which may utilize third-party providers like ...

The associated price target remains the same with $7.00. Douglas Tsao’s rating is based on Coherus Biosciences’ promising data from their Phase 2 study involving a triplet therapy for liver ...